Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 10/20 | 0.52 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3202485 | 0.81 | CTSS (0.49) | CPB2CTSSCTSKTDP1MEN1 | |
| SCHEMBL16500289 | 0.79 | CPB2 (0.45) | CPB2CTSSCTSKTDP1ATM | |
| SCHEMBL16945 | 0.78 | CTSK (0.70) | CPB2CTSSCTSKKMT2AEPHX1 | |
| SCHEMBL21427213 | 0.78 | CTSK (0.70) | CPB2CTSSCTSKKMT2AEPHX1 | |
| SCHEMBL9742302 | 0.78 | CTSK (0.70) | CPB2CTSSCTSKKMT2AEPHX1 | |
| SCHEMBL9742291 | 0.78 | CTSK (0.70) | CPB2CTSSCTSKKMT2AEPHX1 | |
| SCHEMBL8283416 | 0.78 | CTSK (0.70) | CPB2CTSSCTSKKMT2AEPHX1 | |
| SCHEMBL21427220 | 0.78 | CTSK (0.70) | CPB2CTSSCTSKKMT2AEPHX1 | |
| SCHEMBL482062 | 0.78 | CTSK (0.70) | CPB2CTSSCTSKKMT2AEPHX1 | |
| SCHEMBL9556128 | 0.78 | CTSK (0.70) | CPB2CTSSCTSKKMT2AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2104497-B1 | SULFAMIDE DERIVATIVES AS TAFIA INHIBITORS | SANOFI SA (FR) | 2015-02-25 | — | — | EP | disclosed |
| US-8389764-B2 | Urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2013-03-05 | — | — | US | disclosed |
| US-20100035930-A1 | UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | disclosed |
| EP-2104497-A2 | UREA AND SULFAMIDE DERIVATIVES AS TAFIA INHIBITORS | Sanofi-Aventis (FR) | 2009-09-30 | — | — | EP | disclosed |
| WO-2008067909-A2 | UREA AND SULFAMIDE DERIVATIVES AS TAFIA INHIBITORS | SANOFI-AVENTIS (FR) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035930-A1 | UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | TFPI, TFPI2, SERPINE1 | CPB2 61/4885CTSS 132/4885CTSK 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.